Edwards Lifesciences Corporation (NYSE:EW) has received a consensus recommendation of “Buy” from the twenty-four research firms that are currently covering the firm, MarketBeat.com reports. Seven investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $125.72.

EW has been the topic of several analyst reports. Jefferies Group LLC raised their price target on shares of Edwards Lifesciences Corporation from $115.00 to $132.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. Bank of America Corporation raised their price objective on shares of Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a research note on Thursday, July 27th. Stifel Nicolaus reiterated a “buy” rating and set a $130.00 price objective (up previously from $118.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th. Barclays PLC raised their price objective on shares of Edwards Lifesciences Corporation from $108.00 to $120.00 and gave the company an “equal weight” rating in a research note on Thursday, July 27th. Finally, Cowen and Company reiterated an “outperform” rating and set a $135.00 price objective (up previously from $130.00) on shares of Edwards Lifesciences Corporation in a research note on Thursday, July 27th.

ILLEGAL ACTIVITY NOTICE: “Edwards Lifesciences Corporation (EW) Given Average Recommendation of “Buy” by Brokerages” was published by Daily Political and is the sole property of of Daily Political. If you are accessing this piece on another publication, it was stolen and republished in violation of international copyright and trademark legislation. The correct version of this piece can be accessed at https://www.dailypolitical.com/2017/11/21/edwards-lifesciences-corporation-ew-given-average-recommendation-of-buy-by-brokerages.html.

Shares of Edwards Lifesciences Corporation (NYSE:EW) traded up $2.36 during trading hours on Thursday, hitting $109.52. 1,748,057 shares of the company’s stock traded hands, compared to its average volume of 1,634,179. Edwards Lifesciences Corporation has a 12 month low of $81.12 and a 12 month high of $121.45. The firm has a market capitalization of $23,180.00, a price-to-earnings ratio of 29.67, a P/E/G ratio of 1.92 and a beta of 0.46. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33.

Edwards Lifesciences Corporation (NYSE:EW) last announced its quarterly earnings results on Tuesday, October 24th. The medical research company reported $0.84 EPS for the quarter, missing the consensus estimate of $0.86 by ($0.02). Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The firm had revenue of $821.50 million during the quarter, compared to analyst estimates of $833.85 million. During the same quarter in the previous year, the business posted $0.68 EPS. Edwards Lifesciences Corporation’s revenue for the quarter was up 11.1% compared to the same quarter last year. sell-side analysts anticipate that Edwards Lifesciences Corporation will post 3.75 EPS for the current fiscal year.

In other Edwards Lifesciences Corporation news, VP Donald E. Bobo, Jr. sold 5,300 shares of Edwards Lifesciences Corporation stock in a transaction on Tuesday, August 29th. The shares were sold at an average price of $112.15, for a total transaction of $594,395.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, VP Larry L. Wood sold 18,960 shares of Edwards Lifesciences Corporation stock in a transaction on Friday, September 15th. The shares were sold at an average price of $112.58, for a total transaction of $2,134,516.80. The disclosure for this sale can be found here. Insiders sold a total of 158,540 shares of company stock valued at $17,130,243 in the last ninety days. Company insiders own 2.13% of the company’s stock.

Several large investors have recently modified their holdings of the business. GSA Capital Partners LLP boosted its stake in shares of Edwards Lifesciences Corporation by 594.9% during the 3rd quarter. GSA Capital Partners LLP now owns 22,565 shares of the medical research company’s stock valued at $2,467,000 after buying an additional 19,318 shares during the period. Belpointe Asset Management LLC acquired a new stake in shares of Edwards Lifesciences Corporation during the 3rd quarter valued at $354,000. IFM Investors Pty Ltd acquired a new stake in shares of Edwards Lifesciences Corporation during the 3rd quarter valued at $637,000. Dana Investment Advisors Inc. boosted its stake in shares of Edwards Lifesciences Corporation by 772.9% during the 3rd quarter. Dana Investment Advisors Inc. now owns 27,462 shares of the medical research company’s stock valued at $3,002,000 after buying an additional 24,316 shares during the period. Finally, Sterling Capital Management LLC boosted its stake in shares of Edwards Lifesciences Corporation by 6.2% during the 3rd quarter. Sterling Capital Management LLC now owns 25,351 shares of the medical research company’s stock valued at $2,771,000 after buying an additional 1,471 shares during the period. 82.16% of the stock is owned by institutional investors.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Analyst Recommendations for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related companies with MarketBeat.com's FREE daily email newsletter.